Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)

The National Institutes of Health is seeking applications for the Canine Cancer Immunotherapy Network (K9CIN) to support canine cancer immunotherapy clinical trials as indicators of safe and effective cancer treatments in humans. The goal is to continue to support canine immunotherapeutic development and maintain momentum for further development of canine analytics and therapeutics. The network will consist of five U01 awards, with one serving as a multifunctional Network Coordinating Center and four conducting canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities. Key aspects of this opportunity include: • The network will focus on canine cancer immunotherapy clinical trials to benefit both humans and dogs. • Applicants can submit for either the Network Coordinating Center or for conducting canine cancer immunotherapy clinical trials and correlative studies. • The opportunity is open to various types of applicants, including small businesses, nonprofits, and institutions of higher education. • The estimated project start date is Dec 01, 2027, and the estimated award date is also Dec 01, 2027.